Table 2.
Results of SF-36 and WOMAC measures (mean ± SD) of all patients after PAO in our study (PAO total), patients without or with only minor complications (PAO group 1), patients with major complications (PAO group 2) and the control group in comparison to published results in the literature (numbers in parentheses = normal values not mentioned; values transformed to a scale between 1 and 100*)
| SF–36 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAO group 1—no/minor complications | PAO group 2—major complications | Level of significance | PAO total | Control group | Level of significance | Random population (25–34 years) [3] | PAO [2] | THR [21] | THR [17] | THR [7] | THR revisions [7] | |
| Physical functioning | 78.8 ± 15.4 | 72.4 ± 14.8 | 0.134 | 75.8 ± 15.3 | 98.9 ± 1.9 | <0.01 | 95 | 72.7 | 64.3 | 53.8 | ||
| Social functioning | 88.7 ± 20.1 | 92.6 ± 14.5 | 0.596 | 90.5 ± 17.7 | 97.5 ± 6.7 | 0.011 | 89 | 92.1 | 83.6 | 77.7 | ||
| Role-physical | 79.5 ± 21.8 | 75.8 ± 22.2 | 0.739 | 77.8 ± 21.8 | 97.5 ± 6.4 | <0.01 | 90 | 67.1 | 63.6 | 57.1 | ||
| Role-emotional | 86.9 ± 17.3 | 73.7 ± 27.4 | 0.095 | 80.9 ± 23.1 | 94.9 ± 10.1 | <0.01 | 84 | 85.9 | 78.6 | 81.5 | ||
| Functional status | 83.5 ± 15.6 | 78.6 ± 15.5 | 0.266 | 81.3 ± 15.5 | 97.2 ± 4.7 | <0.01 | (49.2) | |||||
| Mental health | 74.1 ± 14.4 | 79.2 ± 13.5 | 0.053 | 76.4 ± 14.1 | 80.9 ± 8.9 | 0.225 | 73 | 84.6 | 77.8 | 78.6 | ||
| Vitality | 68.5 ± 13.3 | 65.6 ± 11.7 | 0.371 | 67.2 ± 12.5 | 75 ± 9.3 | <0.01 | 63 | 66.1 | 63.2 | 60.1 | ||
| Bodily pain | 66.1 ± 21.4 | 62.3 ± 23.7 | 0.339 | 64.4 ± 22.3 | 93.8 ± 11.1 | <0.01 | 84 | 72,2 | 68.6 | 66.2 | ||
| Wellbeing | 69.6 ± 13.9 | 69 ±12.8 | 0.658 | 69.3 ± 13.3 | 83.2 ± 7.1 | <0.01 | (54.7) | |||||
| General health | 80.8 ± 13.9 | 75.8 ± 22.5 | 0.694 | 78.5 ± 18.2 | 84.3 ± 10.6 | 0.226 | 77 | 76.8 | 70.9 | 65.1 | ||
| SF-36 total | 77.9 ± 12.9 | 74.7 ± 13.3 | 0.426 | 76.4 ± 13 | 90.3 ± 4.6 | <0.01 | ||||||
| Health change | 56.5 ± 18.7 | 63.2 ± 20.3 | 0.121 | 59.5 ± 19.5 | 62 ± 13.4 | 0.615 | 60.8 | 58.9 | ||||
| WOMAC | ||||||||||||
| Patients without dysaesthesia | Patients with actual dysaesthesia | Random population (58–64 years) [11] | ||||||||||
| Pain | 23.2 ± 20.9 | 25.3 ± 19.3 | 0.308 | 15.4 ± 7.6 | 30 ± 24.2 | 0.014 | 4.9* | 29.6* | 44* | |||
| Stiffness | 28 ± 21.4 | 33.2 ± 25.8 | 0.639 | 18.6 ± 14.9 | 38.5 ± 25 | <0.01 | 5.4* | 37* | 46* | |||
| Function | 21.5 ± 17.2 | 28.8 ± 19.6 | 0.293 | 18.9 ± 12.7 | 29.4 ± 20.9 | 0.015 | 2.9* | 28.2* | 47* | |||
| WOMAC total | 22.4 ± 17.1 | 28.4 ± 19.7 | 0.511 | 18.1 ± 11.5 | 30.3 ± 20.8 | <0.01 | 3.5 | 46* | ||||
THR total hip replacement
Level of significance was determined with the Kruskal-Wallis test